104 related articles for article (PubMed ID: 28402860)
21. Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate.
Bunse L; Pusch S; Bunse T; Sahm F; Sanghvi K; Friedrich M; Alansary D; Sonner JK; Green E; Deumelandt K; Kilian M; Neftel C; Uhlig S; Kessler T; von Landenberg A; Berghoff AS; Marsh K; Steadman M; Zhu D; Nicolay B; Wiestler B; Breckwoldt MO; Al-Ali R; Karcher-Bausch S; Bozza M; Oezen I; Kramer M; Meyer J; Habel A; Eisel J; Poschet G; Weller M; Preusser M; Nadji-Ohl M; Thon N; Burger MC; Harter PN; Ratliff M; Harbottle R; Benner A; Schrimpf D; Okun J; Herold-Mende C; Turcan S; Kaulfuss S; Hess-Stumpp H; Bieback K; Cahill DP; Plate KH; Hänggi D; Dorsch M; Suvà ML; Niemeyer BA; von Deimling A; Wick W; Platten M
Nat Med; 2018 Aug; 24(8):1192-1203. PubMed ID: 29988124
[TBL] [Abstract][Full Text] [Related]
22. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
Mohrenz IV; Antonietti P; Pusch S; Capper D; Balss J; Voigt S; Weissert S; Mukrowsky A; Frank J; Senft C; Seifert V; von Deimling A; Kögel D
Apoptosis; 2013 Nov; 18(11):1416-1425. PubMed ID: 23801081
[TBL] [Abstract][Full Text] [Related]
23. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
[TBL] [Abstract][Full Text] [Related]
24. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.
Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN
Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362
[TBL] [Abstract][Full Text] [Related]
25. Apoptosis induced by temozolomide and nimustine in glioblastoma cells is supported by JNK/c-Jun-mediated induction of the BH3-only protein BIM.
Tomicic MT; Meise R; Aasland D; Berte N; Kitzinger R; Krämer OH; Kaina B; Christmann M
Oncotarget; 2015 Oct; 6(32):33755-68. PubMed ID: 26418950
[TBL] [Abstract][Full Text] [Related]
26. Association between mutant IDHs and tumorigenesis in gliomas.
Ohba S; Hirose Y
Med Mol Morphol; 2018 Dec; 51(4):194-198. PubMed ID: 29633022
[TBL] [Abstract][Full Text] [Related]
27. Identification and Characterization of Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate Dehydrogenase 1 Homodimer and R132H/Wild-Type Heterodimer.
Brooks E; Wu X; Hanel A; Nguyen S; Wang J; Zhang JH; Harrison A; Zhang W
J Biomol Screen; 2014 Sep; 19(8):1193-200. PubMed ID: 24980596
[TBL] [Abstract][Full Text] [Related]
28. IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
Li K; Ouyang L; He M; Luo M; Cai W; Tu Y; Pi R; Liu A
Oncotarget; 2017 Apr; 8(17):28865-28879. PubMed ID: 28427200
[TBL] [Abstract][Full Text] [Related]
29. Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor-κB activation in a hypoxia-inducible factor 1-α dependent manner.
Wang G; Sai K; Gong F; Yang Q; Chen F; Lin J
Mol Med Rep; 2014 May; 9(5):1799-805. PubMed ID: 24626950
[TBL] [Abstract][Full Text] [Related]
30. A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
Fujii Y; Ogasawara S; Oki H; Liu X; Kaneko MK; Takano S; Kato Y
Biochem Biophys Res Commun; 2015 Oct; 466(4):733-9. PubMed ID: 26381180
[TBL] [Abstract][Full Text] [Related]
31. Mixed lineage kinase 3 connects reactive oxygen species to c-Jun NH2-terminal kinase-induced mitochondrial apoptosis in genipin-treated PC3 human prostate cancer cells.
Hong HY; Kim BC
Biochem Biophys Res Commun; 2007 Oct; 362(2):307-12. PubMed ID: 17707342
[TBL] [Abstract][Full Text] [Related]
32. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.
Tateishi K; Wakimoto H; Iafrate AJ; Tanaka S; Loebel F; Lelic N; Wiederschain D; Bedel O; Deng G; Zhang B; He T; Shi X; Gerszten RE; Zhang Y; Yeh JJ; Curry WT; Zhao D; Sundaram S; Nigim F; Koerner MVA; Ho Q; Fisher DE; Roider EM; Kemeny LV; Samuels Y; Flaherty KT; Batchelor TT; Chi AS; Cahill DP
Cancer Cell; 2015 Dec; 28(6):773-784. PubMed ID: 26678339
[TBL] [Abstract][Full Text] [Related]
33. The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis.
Wang TX; Liang JY; Zhang C; Xiong Y; Guan KL; Yuan HX
Cell Death Dis; 2019 Oct; 10(10):755. PubMed ID: 31591388
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic value of plasma and urinary 2-hydroxyglutarate to identify patients with isocitrate dehydrogenase-mutated glioma.
Lombardi G; Corona G; Bellu L; Della Puppa A; Pambuku A; Fiduccia P; Bertorelle R; Gardiman MP; D'Avella D; Toffoli G; Zagonel V
Oncologist; 2015 May; 20(5):562-7. PubMed ID: 25862748
[TBL] [Abstract][Full Text] [Related]
35. Cyclin F-Dependent Degradation of RBPJ Inhibits IDH1
Deshmukh RS; Sharma S; Das S
Cancer Res; 2018 Nov; 78(22):6386-6398. PubMed ID: 30254149
[TBL] [Abstract][Full Text] [Related]
36. APC selectively mediates response to chemotherapeutic agents in breast cancer.
VanKlompenberg MK; Bedalov CO; Soto KF; Prosperi JR
BMC Cancer; 2015 Jun; 15():457. PubMed ID: 26049416
[TBL] [Abstract][Full Text] [Related]
37. Metabolic syndromes and malignant transformation: where the twain shall meet.
Bhagwat N; Levine RL
Sci Transl Med; 2010 Oct; 2(54):54ps50. PubMed ID: 20962328
[TBL] [Abstract][Full Text] [Related]
38. Mutant IDH1 inhibits PI3K/Akt signaling in human glioma.
Birner P; Pusch S; Christov C; Mihaylova S; Toumangelova-Uzeir K; Natchev S; Schoppmann SF; Tchorbanov A; Streubel B; Tuettenberg J; Guentchev M
Cancer; 2014 Aug; 120(16):2440-7. PubMed ID: 24771584
[TBL] [Abstract][Full Text] [Related]
39. MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells.
Chen J; Miller EM; Gallo KA
Oncogene; 2010 Aug; 29(31):4399-411. PubMed ID: 20514022
[TBL] [Abstract][Full Text] [Related]
40. D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth.
Ma S; Jiang B; Deng W; Gu ZK; Wu FZ; Li T; Xia Y; Yang H; Ye D; Xiong Y; Guan KL
Oncotarget; 2015 Apr; 6(11):8606-20. PubMed ID: 25825982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
